I-Mab acquires Bridge Health, gaining upstream rights to CLDN18.2 antibody, reducing milestone payments for givastomig and eliminating royalties.

I-Mab has solidif | I-Mab has solidified its pivot to givastomig by buying out the owner of an antibody used in the therapy.

The Chinese regulatory agency also cleared the study. About AI-081 AI-081 is a PD-1 and VEGF bispecific antibody with best-in-class potential for the treatment of advanced solid tumors.

- Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral ...

Seemingly harmless SVGs are packed with malicious JavaScript for a phishing redirect to actor-controlled URLs.

A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...

Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies.

A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors significantly improved survival and reduced tumor sizes in animal models ...